Skip navigation
The COVID-19 crisis has profoundly disrupted the pharmaceutical world, reshaping priorities and transforming production methods. Amid a growing demand for biological products, particularly mRNA-based treatments, the industry has been forced to adapt swiftly. For Fareva, this crisis presented an opportunity to reinvent processes and reaffirm its position as a leader in sterile pharmaceutical manufacturing.

 

Market Challenges

The pandemic exposed vulnerabilities in pharmaceutical supply chains and highlighted the critical need for healthcare sovereignty. These challenges accelerated innovation and repositioned CDMOs as pivotal players. At Fareva, we leveraged our financial independence and agility to bolster production capabilities. The rapid development of a COVID-19 vaccine showcased our expertise, particularly in mRNA manufacturing and cold storage management.

 

Investments and Innovations

To anticipate the growth in biological products and potent drugs, Fareva initiated a pilot project for clinical batches, including liquid and lyophilized products. Additionally, we invested in a cutting-edge aseptic filling line equipped with advanced isolator technology to ensure optimal sterility.

Our development capabilities have been further enhanced with a new sterile pilot unit at Fareva Pau, capable of handling products up to OEB5. This complements our Farmea and Excella sites, providing a comprehensive solution for development needs.

To ensure the safety and quality of our products, we updated our aseptic practices in line with the revised GMP guidelines of the European Union. Over €30 million has been invested to modernize our facilities. With the injectable market experiencing significant growth, we expanded our capacity at Valdepharm with a new automated aseptic filling line, effectively meeting client demands.

As part of our innovation strategy, we have established partnerships to develop new injection devices, such as Blow-Fill-Seal (BFS) technology with ready-to-use syringes, further solidifying our leadership position.

 

Concrete Commitments

Innovation extends beyond production technology; it is deeply rooted in our commitment to sustainability.

This is why we have launched decarbonization initiatives and invested in alternative energy sources, validated by certifications like ECOVADIS. Our goal is to combine high-quality production with sustainable practices, offering solutions that benefit both our clients and the planet.

By integrating innovation, sustainability, and expertise, Fareva positions itself as a trusted partner for the future. We are ready to support our clients in their most ambitious projects, delivering tailored solutions that address global challenges and meet tomorrow’s needs.

 

Read the full article: 

 

Learn more about our API activities.